| Literature DB >> 25977469 |
Mitsuharu Kawamura1, Melvin M Scheinman1, Randall J Lee1, Nitish Badhwar1.
Abstract
BACKGROUND: Left atrial appendage (LAA) exclusion has been performed in patients with atrial fibrillation (AF) to prevent thrombus formation and subsequent cardioembolic events. Left atrial electrical remodeling is a recognized factor in the recurrence of AF. The effects of LAA exclusion on P-wave characteristics and left atrial electrical remodeling have not been well described. The purpose of this study was to evaluate the effect of LAA ligation on P-wave morphology in patients with AF. METHODS ANDEntities:
Keywords: P wave; atrial fibrillation; atrial remodeling; left atrial appendage; ligation
Mesh:
Year: 2015 PMID: 25977469 PMCID: PMC4599401 DOI: 10.1161/JAHA.114.001581
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Characteristics of Patients With AF
| Characteristic | LAA Ligation Patients (n=15) |
|---|---|
| Age, y | 64±11 |
| Sex, male | 11 (73%) |
| EF, % | 63±8.3 |
| BMI, kg/m2 | 29±4.3 |
| Paroxysmal AF | 11 (73%) |
| Persistent AF | 4 (27%) |
| Bleeding event | 5 (33%) |
| CHADS2 score | 2.4±1.7 |
| History of CHF | 6 (40%) |
| Hypertension | 11 (73%) |
| Age (≧75 years) | 2 (16%) |
| Diabetes mellitus | 3 (20%) |
| History of stroke | 4 (26%) |
| CHA2DS2-VASc score | 3.1±1.8 |
| HAS-BLED score | 3.1±1.4 |
| Medical therapy, n (%) | |
| Class III | 6 (40%) |
| Class I | 5 (33%) |
| β-Blockers | 11 (73%) |
| ACEI/ARB | 3 (20%) |
| Anticoaguration | 10 (66%) |
AF indicates atrial fibrillation; LAA, left atrial appendage; EF, ejection fraction; BMI, body mass index; CHA2DS2-VASc, estimates risk based on the presence of congestive heart failure, hypertension, aged ≥75 y, diabetes mellitus, and prior stroke or transient ischemic attack plus vascular disease and sex category; CHF, congestive heart failure; HAS-BLED, risk stratification scheme is one of several that has been validated to estimate baseline risk of major hemorrhage (defined as hemorrhage involving a critical anatomic site, for example, intracranial, or a bleed requiring hospitalization, transfusion of ≥2 units of packed cells, or associated with a decrease in hemoglobin level of ≥2 g/L; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin type II blocker.
Clinical Characteristics of Patients With AF
| Patient No. | Age, y | Sex | Type | Ejection Fraction (%) | CHADS2 | Body Mass Index, kg/m2 | Bleeding | Recurrence | Cardioversion | Complication | Flow (LA/LAA) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 62 | F | Paro | 60 | 2 | 34.2 | 0 | AF | N/A | None | (−) |
| 2 | 58 | M | Paro | 61 | 2 | 38.7 | 0 | SR | N/A | None | (−) |
| 3 | 56 | M | Paro | 70 | 1 | 29.8 | 0 | SR | N/A | None | (−) |
| 4 | 60 | M | Paro | 61 | 1 | 22.8 | 1 | AF | N/A | None | (−) |
| 5 | 57 | M | Paro | 58 | 1 | 31.2 | 1 | SR | N/A | Pericarditis | (−) |
| 6 | 82 | F | Paro | 72 | 3 | 29.5 | 0 | AF | N/A | None | (+) |
| 7 | 66 | M | Paro | 66 | 4 | 28.7 | 0 | SR | N/A | None | (−) |
| 8 | 55 | M | Paro | 45 | 3 | 27.2 | 0 | AF | N/A | None | (−) |
| 9 | 71 | M | Paro | 62 | 4 | 32.4 | 1 | AF | N/A | None | (−) |
| 10 | 50 | M | Per | 65 | 1 | 33.3 | 0 | SR | Electrical | None | (−) |
| 11 | 65 | M | Per | 55 | 1 | 33.3 | 0 | SR | Electrical | None | (−) |
| 12 | 82 | M | Per | 63 | 1 | 23.7 | 1 | SR | Pharma | None | (−) |
| 13 | 65 | M | Per | 68 | 2 | 28.1 | 1 | SR | Electrical | None | (−) |
| 14 | 72 | M | Paro | 70 | 3 | 29.2 | 0 | AF | N/A | None | (−) |
| 15 | 59 | F | Paro | 69 | 2 | 28.5 | 0 | SR | N/A | None | (−) |
AF indicates atrial fibrillation; CHADS2, estimates risk based on the presence of congestive heart failure, hypertension, aged ≥75 y, diabetes mellitus, and prior stroke or transient ischemic attack; LA, left atrial; LAA, left atrial appendage; Paro, paroxysmal AF; N/A, not applicable; SR, sinus rhythm; Per, persistent AF; Pharma, pharmacological cardioversion.
Figure 1Changes in PWD before, immediately after LAA ligation, and after 3 months. A, This panel showed the changes in PWD in leads I, II, and III. B, This panel showed the changes in PWD in leads aVR, aVL, and aVF. C, This panel showed the changes in PWD in leads V1, V2, and V3. D, This panel showed the changes in PWD in leads V4, V5, and V6. LAA indicates left atrial appendage; PWD, P-wave duration.
Figure 2Changes in PWA before, immediately after LAA ligation, and after 3 months. A, This panel showed the changes in PWA in leads I, II, and III. B, This panel showed the changes in PWA in leads aVR, aVL, and aVF. C, This panel showed the changes in PWA in leads V1, V2, and V3. D, This panel showed the changes in PWA in leads V4, V5, and V6. LAA indicates left atrial appendage; PWA, P-wave amplitude.
Change in PWD and PWA Before PVI
| Lead | ΔPWD (Immediately After–Before) | ΔPWA (Immediately After–Before) | ||||
|---|---|---|---|---|---|---|
| SR (n=9) | AF (n=6) | SR (n=9) | AF (n=6) | |||
| I | −25 | −5 | 0.01 | −0.02 | −0.01 | 0.78 |
| II | −13 | −9 | 0.51 | 0.06 | 0.03 | 0.31 |
| III | −7.2 | −6.2 | 0.71 | 0.04 | 0.02 | 0.71 |
| aVR | −6.2 | −6.8 | 0.87 | −0.02 | 0.02 | 0.12 |
| aVL | −25 | −12 | 0.04 | −0.03 | −0.01 | 0.61 |
| aVF | −13 | −12 | 0.81 | 0.07 | −0.03 | 0.09 |
| V1 | −8.2 | 3.1 | 0.03 | −0.03 | 0.07 | 0.04 |
| V2 | −10.5 | 2.1 | 0.04 | −0.05 | 0.05 | 0.03 |
| V3 | −3.4 | 1.2 | 0.42 | −0.03 | 0.01 | 0.29 |
| V4 | −4.6 | −4.1 | 0.91 | −0.02 | −0.02 | 0.61 |
| V5 | −6.9 | −9.1 | 0.7 | −0.02 | −0.01 | 0.83 |
| V6 | −7.2 | −5.6 | 0.71 | −0.03 | −0.02 | 0.48 |
AF indicates atrial fibrillation; PVI, pulmonary vein isolation; PWA, P-wave amplitude; PWD, P-wave duration; SR, sinus rhythm.
Figure 3Spaghetti plots of PQ interval and P-wave dispersion with 12 patients before, immediately after left atrial appendage ligation, and after 1 to 3 months.
Figure 4Example of changes in P-wave morphology in a patient who maintained sinus rhythm after left atrial appendage ligation.